· Published by Health Canada · Official notice
This is duplicated text of a letter from Takeda Canada, Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 19, 2012
Subject: Potential association between ACTOS (pioglitazone hydrochloride) and bladder cancer
Takeda Canada, Inc. in collaboration with Health Canada, would like to inform you about new safety information regarding ACTOS and a potential risk of bladder cancer in treated patients. Further to Health Canada’s assessment of safety data, the Product Monograph (PM) was updated to reflect this risk.
ACTOS (pioglitazone hydrochloride) is an antidiabetic medication authorized in Canada to control blood sugar levels in people with type 2 diabetes whose blood sugar levels have not been controlled by diet and exercise. ACTOS may be used alone or in combination with other diabetes drugs (sulfonylurea or metformin).
Available data reveal an association with a potential increased risk of bladder cancer in diabetic patients treated with pioglitazone in particular in patients treated for the longest durations and with the highest total doses. A possible risk after short term treatment cannot be excluded.
A five-year report of an ongoing 10-year study in patients with diabetes (KPNC study) suggested that taking pioglitazone longer than
12 months increased the risk of developing bladder cancer. There was an increase of 3 cases in 10,000 from approximately 7 in 10,000 (without pioglitazone) to approximately 10 in 10,000 (with pioglitazone).
Takeda Canada, Inc.has worked with Health Canada to update the safety information for ACTOS and has sent a letter to health care professionals to inform them of this new safety information. A copy of that letter is available on the Healthy Canadians websiteFootnote1.
The newly revised Product Monograph for ACTOS (pioglitazone hydrochloride) can be accessed on the Web Sites of Health CanadaFootnote2 and Takeda Canada, IncFootnote3. Takeda Canada, Inc. will continue to review new safety data for ACTOS, including post-marketing adverse event reports.
Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Any case of unexpected adverse reactions in patients receiving ACTOS should be reported to Takeda Canada, Inc. or Health Canada at the following addresses:
Takeda Canada, Inc.
435 North Service Road West
Oakville, ON L6M 4X8
Telephone: 1-888-825-3321
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Dr. Brad Pamenter
Vice President, Medical and Scientific Affairs
Takeda Canada, Inc.
ACTOS is a trademark of Takeda Pharmaceutical Company Limited used under license by Takeda Canada, Inc.